Following memory decline in Alzheimer disease
Translational Neuroscience CAG for Alzheimer's Disease
This project will use 7T MRI, EEG, blood and stool samples, and memory tests to see if they can track memory decline in people over 55 with Alzheimer's disease or mild cognitive impairment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Norwegian University of Science and Technology Academic / other |
| Locations | 1 site (Trondheim, Trønderlag) |
| Trial ID | NCT07118137 on ClinicalTrials.gov |
What this trial studies
This observational project enrolls Norwegian-speaking adults over 55 with a confirmed diagnosis of Alzheimer's disease or mild cognitive impairment who live at home. Participants undergo high-resolution 7T MRI, EEG recordings, blood and stool collection, and neuropsychological testing (MoCA) to characterize structural, functional, and biological changes related to memory. People with severe cognitive impairment (planned cutoff CDR > 2), other neurodegenerative diagnoses, brain tumors, prior cranial surgery, or contraindications to the imaging modalities are excluded. The aim is to combine multimodal imaging and biomarkers to identify signals that track memory deterioration over time.
Who should consider this trial
Good fit: Ideal candidates are Norwegian-native adults over 55, living at home, with confirmed Alzheimer's disease or mild cognitive impairment who can undergo 7T MRI and EEG and complete cognitive testing.
Not a fit: Patients with severe cognitive impairment preventing assessments (e.g., CDR > 2), other neurodegenerative diseases, contraindications to 7T MRI or EEG (metal implants, certain pacemakers, large head-area tattoos), or those living in institutions are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could identify imaging and biomarker signals that help predict or monitor memory decline earlier and more accurately.
How similar studies have performed: Prior research using MRI, EEG, and blood biomarkers has shown promise in tracking Alzheimer's-related changes, but combining ultra-high-field 7T MRI with multimodal biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis based on current ICD criteria for AD or MCI . * \>55years. * Norwegian native speaker * Lives at home and not in a health institution Exclusion Criteria: * Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2). * Presence of brain tumors. * History of traumatic brain injury. * History of cranial surgery. * Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG). * Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS. 7T MRI contraindications: * Large tattoos close to the head region, permanent makeup or unremoveable piercings * Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred) * Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)
Where this trial is running
Trondheim, Trønderlag
- Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU) — Trondheim, Trønderlag, Norway (Recruiting)
Study contacts
- Principal investigator: Axel Sandvig Professor, MD PhD — Norwegian University of Science and Technology (NTNU)
- Study coordinator: Axel Sandvig Professor, MD & PhD
- Email: axel.sandvig@ntnu.no
- Phone: +4745840578
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.